Monitoring strontium ranelate therapy in patients with osteoporosis

Osteoporosis International

Volumn 20, Issue 7, 2009, Pages 1101-1106

  Kendler, D L ^a   Adachi, J D ^b   Josse, R G ^c   Slosman, D O ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d Clinique Generale de Beaulieu   (Switzerland)

Author keywords

Bone mineral density; Bone turnover markers; Monitoring osteoporosis therapy; Strontium ranelate

Indexed keywords

ALENDRONIC ACID; PLACEBO; RISEDRONIC ACID; STRONTIUM RANELATE;

ARTIFACT; BIOMECHANICS; BONE BIOPSY; BONE DENSITY; BONE MINERAL; BONE STRENGTH; BONE TURNOVER; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; HIP FRACTURE; HUMAN; ILIAC CREST; LUMBAR SPINE; NONHUMAN; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; TREATMENT OUTCOME; VERTEBRA FRACTURE; X RAY;

BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CLINICAL TRIALS AS TOPIC; FRACTURES, BONE; HUMANS; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS; THIOPHENES; TREATMENT OUTCOME;

EID: 67349173181     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-009-0886-1     Document Type: Review

References (34)

1. R Rizzoli SL Greenspan G Bone TJ Schnitzer NB Watts S Adami AJ Foldes C Roux MA Levine B Uebelhart AC Santora 2nd A Kaur CA Peverly JJ Orloff 2002 Alendronate Once-Weekly Study Group. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis J Bone Miner Res 17 11 1988 96
2. JP Brown DL Kendler MR [tmp] McClung RD Emkey JD Adachi MA Bolognese Z Li A Balske R Lindsay 2002 The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis Calcif Tissue Int 71 2 103 11
3. PD Miller MR [tmp] McClung L Macovei JA Stakkestad M Luckey B Bonvoisin JY Reginster RR Recker C Hughes EM Lewiecki D Felsenberg PD Delmas DL Kendler MA Bolognese N Mairon C Cooper 2005 Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study J Bone Miner Res. 20 8 1315 22
4. S Sarkar BH Mitlak M Wong JL Stock DM Black KD Harper 2002 Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy J Bone Miner Res 17 1 1 10 (Pubitemid 33150990)
5. SR Cummings DB Karpf F Harris 2002 Improvement in spine bone ensity and reduction in risk of vertebral fractures during treatment with antiresorptive drugs Am J Med 112 4 281 289 (Pubitemid 34219441)
6. PD Miller 2005 Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction Curr Osteoporos Rep 3 103 10
7. RD Wasnich PD Miller 2000 Anti-fracture efficacy of anti-resorptive agents are related to changes in bone density J Clin Endoc Metab 85 1 231 236 (Pubitemid 32268819)
8. O Johnell JA Kanis A Oden H Johansson C De Laet P Delmas JA Eisman S Fujiwara H Kroger D Mellstrom PJ Meunier LJ Melton 3rd T O'Neill H Pols J Reeve A Silman A Tenenhouse 2005 Predictive value of BMD for hip and other fractures J Bone Miner Res 20 7 1185 94
9. D. Kendler 2006 Strontium ranelate-data on vertebral and non vertebral fracture efficacy and safety: mechanism of action Current Osteoporosis Reports 4 34 39 (Pubitemid 44623946)
10. JY Reginster E Seeman MC De Vernejoul S Adami J Compston C Phenekos JP Devogelaer M Diaz-Curiel A Sawicki S Goemaere OH Sorensen D Felsenberg PJ Meunier 2005 Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: TROPOS Study JCEM 90 5 2816 2822
11. PJ Meunier C Roux E Seeman S Ortolani JE Badurski TD Spector J Cannata A Balogh E-M Lemmel S Pors-Nielsen R Rizzoli HK Genant J-Y Reginster 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis N Engl J Med 350 459 468 (Pubitemid 38133766)
12. GM Blake EM Lewiecki DL Kendler I Fogelman 2007 A review of strontium ranelate and its effect on DXA scans J Clin Densitom 10 2 113 9
13. G Blake I Fogelman 2005 Bone densitometry: an update editorial Lancet 366 9503 2068 2070 (Pubitemid 41797634)
14. GM Blake I Fogelman 2005 Long-term effect of strontium ranelate treatment on BMD J Bone Miner Res 20 11 1901 4
15. G. Boivin M.T Khebbab X. Jaurand D. Farlay P.J. Meunier PD Delmas 2007 Localization of strontium, by X-ray microanalysis cartography, in bone biopsies of postmenopausal osteoporotic women treated for 3 years with strontium ranelate Calcif Tissue Int 80 S118
16. PJ Meunier DO Slosman PD Delmas 2002 Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis-a 2-year randomized placebo controlled trial J Clin Endocrinol Metab 87 2060 2066 (Pubitemid 34521489)
17. SG Dahl P Allain PJ Marie 2001 Incorporation and distribution of strontium in bone Bone 28 446 453 (Pubitemid 32385418)
18. S Pors Nielsen D Slosman OH Sorensen B Basse-Cathelinat P De Casin C Roux PJ Meunier 1999 Influence of strontium on bone mineral density and bone mineral content measurements by dual x-ray absorptiometry J Clin Densitom 2 371 379
19. P Ammann V Shen B Robin Y Mauras JP Bonjour R Rizzoli 2004 Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats J Bone Miner Res 19 2012 2020 (Pubitemid 41103416)
20. MC Hochberg PD Ross D Black SR Cummings HK Genant MC Nevitt 1999 Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis Fracture Intervention Trial Research Group Arthritis Rheum 42 1246 54
21. PD Delmas Z Li C Cooper 2004 Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with metaanalyses J Bone Miner Res 19 330 7
22. O Bruyere C Roux J Detilleux DO Slosman TD Spector P Fardellone K Brixen JP Devogelaer M Diaz-Curiel C Albanese JM Kau man S Pors-Nielsen JY Reginster 2007 Relation between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate J Clin Endocrinol Metab 92 3076 3081 (Pubitemid 47236373)
23. O Bruyere C Roux J Badurski G Isaia MC De Vernejoul J Cannata S Ortolani D Slosman J Detilleux J-Y Reginster 2007 Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate Curr Med Res Opin 23 12 3041 5
24. NB Watts C Cooper R Lindsay R Eastell MD Manhart IP Barton TP van Staa JD Adachi 2004 Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk J Clin Densitom 7 255 61
25. RD Chapurlat L Palermo P Ramsay SR Cummings 2005 Risk of fracture among women who lose bone density during treatment with alendronate The Fracture Intervention Trial Osteoporos Int 16 842 8
26. P Chen PD Miller PD Delmas DA Misurski JH Krege 2006 Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis J Bone Miner Res 21 1785 90
27. JA Cramer MM Amonkar A Hebborn R Altman 2005 Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis Curr Med Res Opin 21 9 1453 60
28. ML Bouxsein PD Delmas 2008 Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective J Bone Miner Res 23 8 1155 67
29. DM Black AV Schwartz KE Ensrud 2006 Effects of continuing or stopping alendronate after 5 years of treatment-The fracture Intervention Trial Long-term Extension (FLEX): a randomized trial JAMA 396 2927 2938 (Pubitemid 46021497)
30. NB Watts A Chines WP Olszynski CD [tmp] McKeever MR [tmp] McLung X Zhou A Grauer 2008 Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporos Int 2007 Osteoporos Int 19 3 365 72
31. S Ortolani M Diaz-Curiel 2007 Strontium ranelate: changes in BMD one year after treatment discontinuation Osteoporos Int 18 S25
32. D Farlay G Boivin G Panczer A Lalande PJ Meunier 2005 Long-term strontium ranelate administration in monkeys preserves characteristics of bone mineral crystals and degree of mineralization of bone J Bone Miner Res 20 9 1569 1578 (Pubitemid 41243546)
33. S Pors Nielsen O Barenholdt C Barenholdt-Schioler Y Mauras P Allain 2004 Noninvasive measurement of bone strontium J Clinical Densitometry 7 262 268 (Pubitemid 39178893)
34. JY Reginster D Felsenberg S Boonen A Diez-Perez R Rizzoli ML Brandi TD Spector K Brixen S Goemaere C Cormier A Balogh PD Delmas PJ Meunier JY Reginster K Brixen C Cormier J Cannata 2008 Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: results of a five-year, randomized, placebo-controlled trial Arthritis Rheum 58 6 1687 95